The CREB coactivator CRTC2 promotes oncogenesis in LKB1-mutant non–small cell lung cancer
Menée sur des lignées cellulaires de cancer du poumon non à petites cellules et à l'aide de modèles murins, cette étude démontre que CRTC2, une protéine co-activatrice de CREB (cAMP response element-binding protein), favorise la croissance des cellules cancéreuses porteuses d'une mutation au niveau du gène codant pour le suppresseur de tumeur LKB1
The LKB1 tumor suppressor is often mutationally inactivated in non–small cell lung cancer (NSCLC). LKB1 phosphorylates and activates members of the AMPK family of Ser/Thr kinases. Within this family, the salt-inducible kinases (SIKs) modulate gene expression in part via the inhibitory phosphorylation of the CRTCs, coactivators for CREB (cAMP response element-binding protein). The loss of LKB1 causes SIK inactivation and the induction of the CRTCs, leading to the up-regulation of CREB target genes. We identified CRTC2 as a critical factor in LKB1-deficient NSCLC. CRTC2 is unphosphorylated and therefore constitutively activated in LKB1-mutant NSCLC, where it promotes tumor growth, in part via the induction of the inhibitor of DNA binding 1 (ID1), a bona fide CREB target gene. As ID1 expression is up-regulated and confers poor prognosis in LKB1-deficient NSCLC, our results suggest that small molecules that inhibit CRTC2 and ID1 activity may provide therapeutic benefit to individuals with NSCLC.
Science Advances 2019